The Asia Pacific Coronary Heart Disease Diagnostic Imaging Devices Market would witness market growth of 7.3% CAGR during the forecast period (2022-2028).
Intravascular ultrasonography (IVUS), coronary computed tomography (CT) angiography, and magnetic resonance imaging (MRI) are new tomographic cardiovascular imaging procedures that can be utilized to assess atherosclerotic particles for the characterization and early staging of coronary artery disease (CAD). Despite the fact that IVUS pictures have a high resolution and can detect very early preclinical CAD, it is an invasive procedure that is only utilized clinically in conjunction with coronary intervention. Noninvasive multiple-slice coronary CT angiography shows potential as a CAD diagnosis technique. In patients without known CAD, new 64-slice cardiac CT technology shows remarkable accuracy for detecting lesions obstructing more than 50% of the lumen, along with sensitivity, specificity, and positive and negative predictive values all better than 90%. Cardiac MRI improves the accuracy of coronary plaque identification and allows for better plaque characterization. The aim would be to identify plaques earlier in the formation of CAD and to describe the plaques most likely to cause a clinical event as tomographic imaging of coronary atheroma improves.
Market players operating in the regional market have major growth prospects in the region due to the significant prevalence of several cardiovascular disorders. According to the National Library of Medicine, in 2019, China was anticipated to have 5.09 million CVD fatalities, with a mortality rate of 364.5 per 100,000 people and an age-standardized mortality rate of 276.0 per 100,000, respectively. Stroke is the main cause of death, with a mortality rate of 171.6 per 100,000 and an age-standardized mortality rate (ASMR) of 130.0 per 100,000, respectively. Ischemic heart disease was the second leading cause, with a death rate of 147.3 per 100,000 and an ASMR of 142.1 per 100,000, respectively. The two leading causes of CVD mortality, ischemic heart disease, and stroke, accounted for almost 87% of all CVD deaths.
The common people's lifestyle in China has changed dramatically as a result of socioeconomic progress. People are increasingly exposed to cardiovascular-related risk factors in China, especially as the population ages and urbanization accelerates, and the prevalence and incidence of cardiovascular disease (CVD) have increased in the last ten years. According to a 2018 report on CVDs in China, the number of patients with cardiovascular disorders in across the country is estimated to be around 290 million, with approximately 13 million suffering from stroke and approximately 11 million suffering from coronary heart disease. CVD is still the leading cause of death in China, accounting for more than 40% of all fatalities in 2016. Among CVDs, stroke was the leading cause of mortality.
The China market dominated the Asia Pacific Coronary Heart Disease Diagnostic Imaging Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $171.4 Million by 2028. The Japan market is poised to grow at a CAGR of 6.6% during (2022 - 2028). Additionally, The India market would display a CAGR of 7.9% during (2022 - 2028).
Based on Modality, the market is segmented into Nuclear Medicine, Computed Tomography, Ultrasound, X rays, and Magnetic Resonance Imaging. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Coronary Heart Disease Diagnostic Imaging Devices Market is Projected to reach USD 2.1 Billion by 2028, at a CAGR of 6.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Koninklijke Philips N.V., Siemens Healthineers AG, Fujifilm Holdings Corporation, Canon, Inc. (Canon Medical Systems Corporation), Mindray Medical International Limited, Chison Medical Technologies Co., Ltd., and Analogic Corporation (Altaris Capital Partners).
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 